Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

19.0%

4 terminated/withdrawn out of 21 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

50%

8 of 16 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 1
16(76.2%)
Phase 2
2(9.5%)
Phase 3
2(9.5%)
Early Phase 1
1(4.8%)
21Total
Phase 1(16)
Phase 2(2)
Phase 3(2)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT06235281Early Phase 1Suspended

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

Role: collaborator

NCT01571596Phase 1Completed

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Role: collaborator

NCT01611142Phase 2Completed

Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)

Role: collaborator

NCT02127476Phase 1Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT00830674Phase 1Completed

A Study of KRN23 in X-linked Hypophosphatemia

Role: collaborator

NCT01447732Phase 1Completed

Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Role: collaborator

NCT01279291Phase 1Terminated

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Role: collaborator

NCT00838578Phase 1Terminated

Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT00775502Phase 1Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Role: collaborator

NCT02610231Phase 3Completed

Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Role: collaborator

NCT01199367Phase 1Terminated

Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Role: collaborator

NCT00888927Phase 1Completed

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Role: collaborator

NCT01063907Phase 1Completed

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Role: collaborator

NCT01968031Phase 3Completed

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

Role: collaborator

NCT00921336Phase 1Completed

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

Role: collaborator

NCT02174250Phase 1Completed

The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.

Role: collaborator

NCT02609477Phase 1Completed

A Study to Evaluate Abuse Potential of Istradefylline

Role: collaborator

NCT01226472Phase 2Completed

Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Role: collaborator

NCT02256033Phase 1Completed

Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline

Role: collaborator

NCT02281409Phase 1Completed

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Role: collaborator